Toxoplasmosis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Clinical Presentation
  5. Diagnosis
  6. Treatment
  7. Complications
  8. Prevention
  9. Research and Advances
  10. Key Research Papers
  11. PubMed Topic Searches
  12. Connections
  13. Featured Videos

Overview

Toxoplasmosis is an infection caused by Toxoplasma gondii, an obligate intracellular protozoan parasite that infects virtually all warm-blooded animals. It holds the distinction of being the most common protozoan infection globally as measured by seroprevalence, with an estimated one-third of the world’s population carrying latent infection.

The parasite has a complex two-host life cycle. Cats and other felids are the only definitive hosts — meaning the sexual stage of the parasite’s reproduction occurs exclusively in their intestinal epithelium, producing oocysts that are shed in feces. A single acutely infected cat can shed hundreds of millions of oocysts over a two-week window; those oocysts sporulate in the environment within 1–5 days and remain infectious in warm moist soil for up to 18 months.

Humans acquire infection through three primary routes:

In healthy adults, toxoplasmosis is almost always silent or causes only a mild, self-limited illness resembling mononucleosis. The danger arises in two groups: immunocompromised patients (particularly those with AIDS and CD4 counts below 100 cells/μL), in whom latent cysts can reactivate to cause life-threatening encephalitis; and fetuses infected in utero, who face risks of chorioretinitis, hydrocephalus, and severe developmental impairment.

Seroprevalence in the United States is approximately 10–15% of the general population, but in France, Brazil, and much of sub-Saharan Africa it exceeds 50–80%, reflecting differences in meat-eating habits, cat density, climate, and sanitation.

Back to Table of Contents

Epidemiology

Toxoplasma gondii infects an estimated 30% of the global human population, making it one of the most successful parasitic infections in history. Geographic distribution is worldwide, but seroprevalence is strikingly unequal.

High-prevalence regions include France (up to 54%), Brazil (up to 78% in some studies), Ethiopia, Turkey, and parts of Southeast Asia and Latin America. Low-prevalence regions include northern Europe, North America, and Southeast Asia outside of continental areas. The United States has seen seroprevalence fall over decades, from roughly 23% in NHANES 1988–1994 to approximately 13% in 2009–2010, possibly reflecting changed meat-handling practices and indoor cat ownership.

Key risk factors in the US and Europe:

Congenital toxoplasmosis occurs when a woman who has never been infected acquires primary T. gondii infection during pregnancy and the parasite crosses the placenta. Approximately 4,000 cases of congenital toxoplasmosis occur annually in the United States, and the economic burden of lifetime care for affected children exceeds $750 million per year. First-trimester infection carries a lower transmission rate (~15%) but causes the most severe fetal damage; third-trimester infection transmits more frequently (~60–65%) but usually causes subclinical disease at birth, with late-onset eye and neurological problems emerging months to years later.

Immunocompromised populations are at risk of life-threatening reactivation. Before modern antiretroviral therapy, toxoplasmic encephalitis was the most common cause of focal brain lesions in AIDS patients, accounting for 50–60% of such cases. The risk is highest when CD4 falls below 100 cells/μL in a Toxoplasma IgG-positive patient who is not on prophylaxis.

Back to Table of Contents

Pathophysiology

Understanding how T. gondii causes disease requires following its journey through three distinct parasite forms: oocysts (shed in cat feces), tachyzoites (the fast-replicating acute form), and bradyzoites (the slow-replicating cyst form that persists in tissue for life).

Entry and transformation. After a human ingests oocysts from contaminated food or soil, stomach acid and pancreatic enzymes degrade the oocyst wall, releasing sporozoites. These penetrate intestinal epithelial cells and transform into tachyzoites, the rapidly dividing asexual form. Similarly, if tissue cysts in undercooked meat are ingested, the low pH of the stomach disrupts the cyst wall, releasing bradyzoites that convert to tachyzoites in the intestinal mucosa.

Hematogenous dissemination. Tachyzoites infect macrophages and dendritic cells in the intestinal lamina propria. Rather than being destroyed, they hijack these professional phagocytes to hitch a ride through the bloodstream and lymphatics — a Trojan horse strategy that allows dissemination to the brain, retina, skeletal muscle, and myocardium.

Parasite immune evasion. T. gondii is a master of intracellular immune evasion. It resides within a specialized vacuole called the parasitophorous vacuole membrane (PVM) that it constructs as it enters the cell. The PVM:

Cyst formation and latency. Immune pressure — primarily from IFN-γ produced by NK cells and T lymphocytes — forces tachyzoites to convert into bradyzoites, which build a thick-walled tissue cyst. Cysts are most common in neurons and skeletal muscle cells. They can contain hundreds to thousands of bradyzoites and remain dormant in immunocompetent hosts for the lifetime of the individual without causing symptoms. IgG antibodies persist lifelong as a marker of this latent infection.

Reactivation in immunosuppression. When T-cell-mediated immunity fails — as in untreated HIV infection, immunosuppressive therapy after organ transplant, or lymphoma — bradyzoites convert back to tachyzoites. In the brain, this produces toxoplasmic encephalitis: rapidly expanding foci of necrosis surrounded by inflammatory infiltrate, classically appearing as multiple ring-enhancing lesions on MRI. Without treatment, progressive cerebral destruction is fatal.

Congenital disease mechanism. Tachyzoites in the maternal bloodstream can cross the placental barrier. The fetal immune system, which is tolerogenic by design, cannot mount effective T-cell responses against the parasite. Tachyzoites replicate unchecked, destroying developing neural tissue and the retina.

Back to Table of Contents

Clinical Presentation

The clinical picture of toxoplasmosis varies dramatically depending on the host’s immune status and whether infection is acquired, reactivated, congenital, or ocular.

Immunocompetent Adults

Approximately 80–90% of primary infections in healthy adults are completely asymptomatic. The remaining 10–20% develop a self-limited illness that closely mimics infectious mononucleosis:

Rare complications in otherwise healthy people include pneumonitis, myocarditis, polymyositis, and hepatitis. These are more common in primary infections acquired in immunocompetent adults in endemic areas.

Toxoplasmic Encephalitis (Immunocompromised)

Reactivation in AIDS (CD4 <100 cells/μL) or transplant recipients produces toxoplasmic encephalitis (TE), the most devastating form of the disease. Onset is subacute over days to weeks:

Brain imaging is essential. MRI is more sensitive than CT. The classic finding is multiple ring-enhancing lesions at the gray-white junction and in the basal ganglia and thalami. The “eccentric target sign” on MRI (a small eccentric nodule within the ring of enhancement) is highly specific for toxoplasmosis. Mass effect and surrounding edema are common. A single lesion, or a lesion in the corpus callosum, should raise suspicion for primary CNS lymphoma instead. Because brain biopsy carries risks, empiric treatment with anti-Toxoplasma drugs is standard; clinical and radiological improvement within 2 weeks is considered diagnostic.

Congenital Toxoplasmosis

The classic triad of congenital toxoplasmosis taught in medical school is:

  1. Chorioretinitis (most common finding, affects 75–80% of symptomatic neonates)
  2. Hydrocephalus
  3. Intracranial calcifications

However, up to 75% of infected newborns appear normal at birth. Late sequelae — emerging months to years later — include retinochoroiditis, sensorineural hearing loss, cognitive impairment, and epilepsy. First-trimester infections, while less frequent, cause the most severe outcomes: spontaneous abortion, stillbirth, or extensive brain destruction. Gestational age at infection is the single strongest predictor of severity.

Ocular Toxoplasmosis

Toxoplasmosis is the most common cause of infectious posterior uveitis worldwide. It can result from congenital infection (reactivating years later) or acquired infection. The hallmark is a focal area of active retinal necrosis adjacent to an old chorioretinal scar — described as a “headlight in the fog” (white fluffy active lesion adjacent to a pigmented scar). Symptoms include blurred vision, floaters, photophobia, and scotoma. Recurrences are common, and each episode can enlarge the scar and threaten vision — particularly when lesions encroach on the macula or optic disc.

Back to Table of Contents

Diagnosis

Diagnosing toxoplasmosis requires integrating serological results, clinical context, imaging, and sometimes direct parasite detection. No single test is definitive in all settings.

Serology

IgG and IgM antibodies are the foundation of diagnosis. IgM appears within 1–2 weeks of infection, peaks within a month, and typically declines over 6–9 months — but can persist for up to 18 months, limiting its utility in distinguishing recent from past infection. IgG appears slightly later, reaches peak titers at 1–2 months, and persists for life.

The IgG avidity test resolves the “IgM still positive” problem: low IgG avidity indicates infection within the past 3–5 months; high avidity effectively rules out recent infection. This is especially important in pregnancy — a high-avidity result in the first trimester means infection predated conception and the fetus is likely not at risk.

In immunocompromised patients, serology can be misleading: anti-Toxoplasma IgG is typically positive (confirming prior infection and reactivation risk), but IgM and rising IgG titers may be absent due to the failure to mount a humoral response. A positive Toxoplasma IgG in an HIV patient with CD4 <100 is sufficient to establish reactivation risk without further serological workup.

Neuroimaging

MRI with gadolinium is the imaging study of choice for suspected toxoplasmic encephalitis. It is more sensitive than CT, revealing lesions missed by CT in up to 15% of cases. Classic findings: multiple ring-enhancing lesions (usually >1 cm) with surrounding edema, bilateral, preferentially in the basal ganglia and frontal-parietal junction. The eccentric target sign (a T2 hypointense nodule off-center within the ring) reaches specificities of 71–72% when present. A single lesion strongly suggests primary CNS lymphoma, especially in an EBV-positive patient.

CSF Analysis and PCR

Lumbar puncture findings in TE are non-specific: mild lymphocytic pleocytosis and elevated protein in about half of cases. CSF PCR for T. gondii has a sensitivity of only 50–60% in TE but is highly specific (>95%). A positive CSF PCR confirms the diagnosis; a negative result does not exclude it. PCR is more useful in amniotic fluid for confirming fetal infection (sensitivity 64–92% when performed after 18 weeks gestation).

Brain Biopsy

Stereotactic brain biopsy is the gold standard when empiric therapy fails or the diagnosis is uncertain. Histology shows tachyzoites and/or bradyzoites within tissue cysts in a background of inflammatory necrosis. Immunohistochemistry enhances sensitivity. Biopsy is generally reserved for patients who deteriorate on empiric therapy after 2 weeks.

Neonatal and Congenital Screening

In the US, universal newborn screening for congenital toxoplasmosis is performed in Massachusetts and New Hampshire using neonatal blood spot IgM and IgA assays. Ophthalmologic examination is mandatory for all confirmed cases. Confirmatory testing at a reference laboratory (National Reference Laboratory for Toxoplasmosis) uses multi-test serological panels.

Back to Table of Contents

Treatment

Treatment decisions in toxoplasmosis depend on which form of disease is present, the patient’s immune status, and pregnancy status. The cornerstone agents are pyrimethamine (a dihydrofolate reductase inhibitor) and sulfadiazine (a sulfonamide), which act synergistically against tachyzoites. Neither drug reliably kills bradyzoites in tissue cysts, which is why immunocompromised patients require lifelong suppressive therapy.

Toxoplasmic Encephalitis in Immunocompromised Patients

First-line acute treatment (6 weeks minimum):

Alternative for sulfa allergy: Pyrimethamine + Clindamycin 600 mg every 6 hours (comparable efficacy in trials; diarrhea is the main side effect). Other alternatives with limited data include pyrimethamine + atovaquone, or TMP-SMX alone for mild immunosuppression.

Maintenance Therapy (Secondary Prophylaxis)

After acute treatment, immunocompromised patients require indefinite suppressive therapy to prevent relapse:

Primary Prophylaxis in HIV

HIV-positive patients with CD4 <100 cells/μL who are Toxoplasma IgG-positive should receive primary prophylaxis to prevent first episode of TE: Trimethoprim-sulfamethoxazole (TMP-SMX) 1 double-strength tablet daily. This is the same regimen used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, so coverage is achieved with one pill. Discontinue when CD4 >200 for ≥3 months.

Immunocompetent Patients

Most healthy adults with symptomatic primary toxoplasmosis do not require treatment — the illness is self-limited. Treatment is considered for:

Regimen: Pyrimethamine + Sulfadiazine + Leucovorin for 4–6 weeks.

Congenital Toxoplasmosis

All infants with confirmed congenital toxoplasmosis receive treatment for 12 months regardless of whether they appear symptomatic at birth, because subclinical disease at birth does not reliably predict the absence of long-term sequelae. Standard regimen: Pyrimethamine + Sulfadiazine + Leucovorin for 12 months (with monthly CBC monitoring for pyrimethamine toxicity). Prednisone is added when CSF protein is ≥1 g/dL or active chorioretinitis threatens vision.

Toxoplasmosis in Pregnancy

Management depends on gestational age and whether fetal infection is confirmed:

Note: Spiramycin is not FDA-approved in the United States and must be obtained through the FDA under an IND (Investigational New Drug) protocol.

Ocular Toxoplasmosis

Vision-threatening lesions (posterior pole, threatening macula or optic disc) require treatment: Pyrimethamine + Sulfadiazine + Leucovorin, with oral prednisone added 24–48 hours after starting anti-parasitic therapy to control the inflammatory response. Duration: 4–6 weeks, with ophthalmology follow-up. Peripheral lesions in immunocompetent patients may be observed without treatment. Consider long-term intermittent prophylaxis (trimethoprim-sulfamethoxazole 3 days/week) in patients with frequent recurrences.

Back to Table of Contents

Complications

The complications of toxoplasmosis range from mild and reversible to permanently disabling or fatal, depending largely on immune status and the organ system involved.

Central nervous system. Toxoplasmic encephalitis left untreated in AIDS patients is universally fatal. Even with treatment, survivors may be left with permanent neurological deficits: focal weakness, aphasia, cognitive impairment, epilepsy, or vision loss from optic nerve involvement. Hydrocephalus requiring shunting develops in a minority of cases. In transplant recipients, TE carries mortality of 50–70% even with treatment, reflecting the depth of iatrogenic immunosuppression.

Immune reconstitution inflammatory syndrome (IRIS). When ART is initiated in an AIDS patient with occult or partially treated TE, rapid recovery of T-cell function can trigger paradoxical worsening — IRIS. Cerebral IRIS presents as new or enlarging ring-enhancing lesions, headache, and fever in the context of falling viral load and rising CD4 count. Management includes continuing ART plus corticosteroids.

Treatment toxicity. The standard pyrimethamine + sulfadiazine regimen has significant side effects: bone marrow suppression (neutropenia, thrombocytopenia, anemia) from pyrimethamine’s folate antagonism, which is mitigated but not eliminated by leucovorin; Stevens-Johnson syndrome and toxic epidermal necrolysis from sulfadiazine (<1% but potentially fatal); nephrotoxicity from sulfadiazine crystalluria (prevent by adequate hydration and urine alkalinization); and rash, nausea, and vomiting.

Ocular complications. Each episode of ocular reactivation can expand the chorioretinal scar. Lesions near the macula cause permanent central scotoma and legal blindness. Extensive bilateral disease can cause total blindness. Retinal detachment is a rare but devastating complication of large lesions.

Congenital long-term outcomes. Children with symptomatic congenital toxoplasmosis face severe developmental delay, cerebral palsy, epilepsy refractory to treatment, cortical blindness, and profound sensorineural hearing loss. Those treated for 12 months have significantly better cognitive and visual outcomes than untreated historical cohorts, but long-term surveillance is required because chorioretinitis can recur through adolescence and adulthood even in treated individuals.

Back to Table of Contents

Prevention

Because most human infections come from two sources — undercooked meat and cat-feces-contaminated soil — prevention is practical and evidence-based. Most cases in the US are preventable.

Food Safety

Cat-Related Precautions

Medical Prophylaxis in High-Risk Patients

Blood Product Safety

Transfusion-transmitted toxoplasmosis is rare but documented in granulocyte transfusion recipients. Seropositive blood products should be avoided in seronegative immunocompromised recipients when possible. Leukoreduction reduces (but does not eliminate) risk.

Back to Table of Contents

Research and Advances

Toxoplasma research has accelerated since the 1990s, driven both by the AIDS epidemic and by the parasite’s extraordinary utility as a model intracellular pathogen. Several areas hold particular promise for patients and public health.

Behavioral manipulation hypothesis. One of the most intriguing areas of toxoplasmosis research is whether latent T. gondii infection alters human behavior. Epidemiological studies have associated Toxoplasma seropositivity with personality trait shifts (slightly higher novelty-seeking and risk-taking in men), slower reaction times, and — controversially — increased incidence of schizophrenia. The proposed mechanism involves parasite-induced upregulation of dopamine biosynthesis in neurons. The data are correlational and confounded; no causation has been established. The topic remains scientifically active and provocative.

Anti-bradyzoite agents. Current drugs (pyrimethamine, sulfadiazine) are highly effective against tachyzoites but do not kill bradyzoites in tissue cysts, which is why lifelong secondary prophylaxis is needed in immunocompromised patients. Atovaquone, a mitochondrial electron-transport inhibitor, shows anti-bradyzoite activity in vitro and in murine models. Combination strategies with endochin-like quinolones (ELQs) that inhibit the Toxoplasma mitochondrial cytochrome bc1 complex are under investigation and could one day allow true sterilizing cure of latent infection.

Calcium-dependent protein kinases (CDPKs). T. gondii CDPKs are attractive drug targets because they are essential for parasite motility, invasion, and egress from host cells, and have no close mammalian homologs (humans lack the plant-like EF-hand calcium-binding domain found in parasite CDPKs). High-throughput screening has identified bumped kinase inhibitors (BKIs) — ATP-competitive compounds with a bulky substituent that exploits the unique glycine gatekeeper residue in Toxoplasma CDPKs. BKIs are in preclinical development.

Rapid field diagnostics. Loop-mediated isothermal amplification (LAMP) assays for T. gondii DNA amplify target sequences at a single temperature (65°C) within 60 minutes with sensitivity approaching PCR. Point-of-care LAMP strips readable by eye could enable prenatal screening and field diagnosis in low-resource settings where laboratory infrastructure is limited.

Vaccine development. No human vaccine exists for toxoplasmosis. A killed-oocyst veterinary vaccine (Toxovax) protects sheep from abortion caused by congenital toxoplasmosis. Research is ongoing into live-attenuated and subunit vaccine approaches using surface antigens (SAG1/p30, SAG2) and secreted proteins (GRA, ROP). A fully effective human vaccine would dramatically reduce congenital toxoplasmosis in endemic regions.

Back to Table of Contents

Key Research Papers

  1. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–1976. DOI: 10.1016/S0140-6736(04)16412-X — PMID 15194258
  2. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–296. DOI: 10.1128/CMR.05013-11 — PMID 22491772
  3. Bhopale GM. Pathogenesis of toxoplasmosis. Comp Immunol Microbiol Infect Dis. 2003;26(4):213–222. DOI: 10.1016/S0147-9571(02)00058-9 — PMID 12676082
  4. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643–1648. DOI: 10.1056/NEJM199212033272306 — PMID 1359590
  5. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993;329(14):995–1000. DOI: 10.1056/NEJM199309303291403 — PMID 8366923
  6. Jones JL, Kruszon-Moran D, Rivera HN, et al. Toxoplasma gondii seroprevalence in the United States 2009–2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014;90(6):1135–1139. DOI: 10.4269/ajtmh.13-0487 — PMID 24710615
  7. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39(12):1385–1394. DOI: 10.1016/j.ijpara.2009.04.003 — PMID 19433092
  8. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR-4):1–207. PMID 19357635
  9. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol. 1999;180(2):410–415. DOI: 10.1016/S0002-9378(99)70224-3 — PMID 9988811
  10. Maenz M, Schlüter D, Liesenfeld O, et al. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77–106. DOI: 10.1016/j.preteyeres.2013.12.005 — PMID 24369326
  11. Dabritz HA, Conrad PA. Cats and Toxoplasma: implications for public health. Zoonoses Public Health. 2010;57(1):34–52. DOI: 10.1111/j.1863-2378.2009.01273.x — PMID 19744306
  12. Pleyer U, Gross U, Schlüter D, et al. Toxoplasmosis in Germany: an interdisciplinary overview. Dtsch Arztebl Int. 2019;116(26):435–444. DOI: 10.3238/arztebl.2019.0435 — PMID 31452487

Back to Table of Contents

PubMed Topic Searches

Search current literature on PubMed for the latest research on toxoplasmosis:

  1. Toxoplasmic encephalitis AIDS treatment
  2. Congenital toxoplasmosis outcomes treatment
  3. Toxoplasma gondii seroprevalence epidemiology
  4. Ocular toxoplasmosis uveitis treatment
  5. Pyrimethamine sulfadiazine toxoplasmosis
  6. Toxoplasma gondii behavioral effects humans
  7. Toxoplasma IgG avidity pregnancy diagnosis
  8. Toxoplasma ring-enhancing lesion MRI brain

Back to Table of Contents

Connections

Back to Table of Contents